{"id":"NCT00998881","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Monotherapy Study of MP-513 in Patients With Type 2 Diabetes","officialTitle":"A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2009-10-21","resultsPosted":"2014-02-21","lastUpdate":"2014-02-21"},"enrollment":203,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Teneligliptin 20 mg","otherNames":["MP-513"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Teneligliptin 20 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 12","timeFrame":"12 weeks","effectByArm":[{"arm":"Placebo","deltaMin":0.17,"sd":0.05},{"arm":"Teneligliptin 20 mg","deltaMin":-0.62,"sd":0.05}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":104},"commonTop":["Nasopharyngitis","Glucose urine present","Upper respiratory tract inflammation","Bronchitis","Blood creatine phosphokinase increased"]}}